Skip to main content

Advertisement

Table 3 Prevalence per 100 and 95% CIs for the use of six* selected psychotropic drugs during the year 2000

From: A three-country comparison of psychotropic medication prevalence in youth

  US (n = 127,157) Netherlands (n = 110,944) Germany (n = 356,520)
  Male Female Total* Male Female Total* Male Female Total*
Alpha-Agonist 0.74 0.18 0.47 0.07 0.02 0.05 0 0 0
  0.62–0.86 0.14–0.22 0.43–0.51 0.05–0.1 0.01–0.03 0.03–0.07 0–0.01 0–0.3 0–0.03
Lithium 0.18 0.13 0.15 0 0.01 0.01 0 0 0
  0.08–0.25 0.06–0.21 0.07–0.23 0–0.02 0–0.02 0–0.02 0–0 0–0.01 0–0.1
Anxiolytic 0.51 0.47 0.49 0.65 0.81 0.73 0.4 0.42 0.41
  0.46–0.58 0.41–0.54 0.42–0.55 0.6–0.74 0.74–0.92 0.68–0.81 0.36–0.44 0.38–0.46 0.38–0.44
Hypnotic 0.15 0.17 0.16 0.35 0.32 0.33 0.08 0.11 0.09
  0.12–0.2 0.14–0.21 0.14–0.21 0.31–0.41 0.27–0.4 0.3–0.39 0.07–0.09 0.1–0.14 0.07–0.13
Antiparkinsonian 0.07 0.04 0.05 0.01 0.01 0.01 0.01 0.01 0.01
  0.03–0.09 0.01–0.07 0.02–0.07 0–0.02 0–0.02 0.01–0.02 0.01–0.02 0–0.02 0.0–0.02
ATC-MS 1.03 0.49 0.77 0.36 0.38 0.37 0.39 0.37 0.38
  0.94–1.12 0.42–0.54 0.72–0.84 0.32–0.42 0.32–0.43 0.33–0.41 0.37–0.43 0.35–0.41 0.37–0.41
  1. *Of the 9 classes comprising “any psychotropic prevalence”. Data on antipsychotics, stimulants and antidepressants are shown in Tables 4, 5 and 6, respectively.
  2. *Totals were adjusted to the child and adolescent population of the US 2000 census by the direct standardization method.